Table 1.
Patient characteristics of stage IV NSCLC patients treated with immunotherapy and chemotherapy.
| Characteristics | Immunotherapy (n = 221) | Chemotherapy (n = 221) | p-value |
|---|---|---|---|
| Age (median ± SD) | 64.0 ± 9.0 | 64.1 ± 8.9 | 0.83 |
| Gender | 131 (59.2%) | 131 (59.2%) | 1.0 |
| BMI (median ± SD) | 25.0 ± 6.3 | 25.0 ± 4.1 | 0.82 |
| Line of treatment | 1.0 | ||
| 1 | 84 (38.0%) | 84 (38.0%) | |
| 2 | 120 (54.3%) | 120 (54.3%) | |
| 3 | 17 (7.7%) | 17 (7.7%) | |
| ECOG PS | < 0.001 | ||
| 0 | 70 (31.7%) | 104 (47.1%) | |
| 1 | 138 (62.4%) | 88 (39.8%) | |
| 2 | 10 (4.5%) | 19 (8.6%) | |
| ≤ 3 | 2 (0.9%) | 4 (1.8%) | |
| Unknown | 1 (0.5%) | 6 (2.7%) | |
| Immunotherapy | |||
| Nivolumab | 121 (54.8%) | ||
| Pembrolizumab | 93 (42.1%) | ||
| Atezolizumab | 7 (3.0%) | ||
| Chemotherapy | |||
| Cisplatin/pemetrexed | 14 (6.3%) | ||
| Cisplatin/gemcitabine | 5 (2.3%) | ||
| Carboplatin/pemetrexed | 57 (31.3%) | ||
| Carboplatin/gemcitabine | 17 (7.7%) | ||
| Carboplatin/paclitaxel/bevacizumab | 21 (9.5%) | ||
| Pemetrexed monotherapy | 46 (20.8%) | ||
| Docetaxel monotherapy | 58 (26.2%) | ||
| Other | 3 (1.4%) | ||
| Histology | < 0.001 | ||
| Adenocarcinoma | 176 (79.6%) | 132 (59.7%) | |
| Squamous | 24 (10.9%) | 40 (18.1%) | |
| Large cell carcinoma | 10 (4.5%) | 17 (7.7%) | |
| Other | 11 (4.9%) | 32 (14.5%) | |
| PD-L1 expression | |||
| < 1% | 34 (15.4%) | ||
| 1–50% | 28 (12.7%) | ||
| > 50% | 100 (45.2%) | ||
| Unknown | 60 (27.1%) | ||
| Targetable mutations | 0.58 | ||
| EGFR | 5 (2.3%) | 6 (2.7%) | |
| ALK | 0 | 1 (0.5%) | |
| Other | 5 (2.3%) | 0 | |
| Brain metastasis (yes) | 49 (22.2%) | 43 (19.5%) | 0.48 |
Abbreviations: ECOG PS, Eastern Cooperative Group performance status; BMI, Body mass index; PD-L1, programmed death ligand-1.